公开(公告)号：US20210221852A1

公开(公告)日：2021-07-22

申请号：US17215636

申请日：2021-03-29

申请人： Boehringer Ingelheim Animal Health USA Inc.

发明人： Luis Alejandro HERNANDEZ ,  Christine Margaret MUEHLENTHALER ,  Eric Martin VAUGHN ,  Gregory HAIWICK

IPC分类号： C07K14/005 ,  C12N7/00 ,  A61K39/12 ,  C12P21/02

摘要： Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

公开(公告)号：US20240076321A1

公开(公告)日：2024-03-07

申请号：US18516237

申请日：2023-11-21

申请人： Boehringer Ingelheim Animal Health USA Inc.

发明人： Luis Alejandro HERNANDEZ ,  Christine Margaret MUEHLENTHALER ,  Eric Martin VAUGHN ,  Gregory HAIWICK

IPC分类号： C07K14/005 ,  A61K39/12 ,  C12N7/00 ,  C12P21/02

CPC分类号： C07K14/005 ,  A61K39/12 ,  C12N7/00 ,  C12P21/02 ,  A61K39/00 ,  C12N2750/10022 ,  C12N2750/10023 ,  C12N2750/10034

摘要： Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.